INSM Q4 2023 Earnings — Insmed Incorporated Revenue & Financial Results | Market Cap Arena

INSMInsmed Incorporated

$31B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$84M+41.1% YoY

Gross Profit

$65M78.0% margin

Operating Income

-$178M-213.0% margin

Net Income

-$186M-222.3% margin

EPS (Diluted)

$-1.28

QoQ Revenue Growth

+5.8%

Cash Flow

Operating Cash Flow

-$131M

Free Cash Flow

-$133M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$1.7B

Stockholders' Equity

-$332M

Cash & Equivalents

$482M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$84M	$59M	+41.1%
Gross Profit	$65M	$46M	+41.1%
Operating Income	-$178M	-$151M	-17.7%
Net Income	-$186M	-$160M	-16.2%

Geographic Segments

UNITED STATES

$58M70%

JAPAN

$21M25%

Europe And The Rest Of The World

$4M5%